Innovative Medicines Initiative (IMI 2)
The Innovative Medicines Initiative (IMI) is working to improve health by speeding up the development of, and patient access to, the next generation of medicines, particularly in areas where there is an unmet medical or social need. It does this by facilitating collaboration between the key players involved in healthcare research, including universities, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators.
IMI is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI has a budget of €3.276 billion for the period 2014-2024. Half of this comes from the EU. The other half comes from large companies, mostly from the pharmaceutical sector; these do not receive any EU funding, but contribute to the projects ‘in kind’, for example by donating their researchers’ time or providing access to research facilities or resources.
IMI was launched in 2008 and currently has 46 ongoing projects, with more in the pipeline. Some focus on specific health issues such as neurological conditions (Alzheimer’s disease, schizophrenia, depression, chronic pain, and autism), diabetes, lung disease, oncology, inflammation & infection, tuberculosis, and obesity. Others focus on broader challenges in drug development like drug and vaccine safety, knowledge management, the sustainability of chemical drug production, the use of stem cells for drug discovery, drug behaviour in the body, the creation of a European platform to discover novel medicines, and antimicrobial resistance. In addition to research projects, IMI supports education and training projects
Giving researchers from diverse sectors the opportunity to participate in ambitious public-private partnerships that will pave the way for the development of the medicines of the future. IMI warmly encourages small and medium-sized enterprises (SMEs), medium-sized companies, patients’ organisations, regulatory authorities, academic teams, industry, hospitals and other organisations to form consortia and apply to participate in the new IMI projects.
IMI2 Call 10 has been launched!
Call budget: €173 890 000
• Understanding hypoglycaemia: the underlying mechanisms and addressing clinical determinants as well as consequences for people with diabetes by combining databases from clinical trials
• How big data could support better diagnosis and treatment outcomes for prostate cancer (part of the Big Data for Better Outcomes programme)
• Improving the care of patients suffering from acute or chronic pain (this topic includes three subtopics on patient reported outcomes; biomarkers; and chronic pelvic pain)
• Creation of a pan-European paediatric clinical trials network
• Biomanufacturing 2020: development of innovative high throughput analytical tools and methods to characterize cell culture fluid during development and commercial cell culture processes
• Unlocking the solute carrier gene-family for effective new therapies (unlock SLCs)
• Patient perspectives in medicines lifecycle
• Personalised medicine approaches in autism spectrum disorders
Deadline: 2-stage call for proposals, deadline for short proposals: 28 March 2017
Webinars: Information about the IMI 2 - Call 10 webinars can be found at http://www.imi.europa.eu/events/2016/11/28/webinars-imi-2-call-10.
A webinar on rules and procedures of the IMI Calls for proposals will take place on 9/1/2017.
Find projects partners: Search for project partners via the Partner Search Tool: http://www.imi.europa.eu/content/partner-search
Presentations from the IMI Stakeholder Forum 2015